The role of cytokines in rheumatoid arthritis: Inhibition of cytokines in therapeutic trials

Drugs of Today

Volumn 35, Issue 4-5, 1999, Pages 309-319

  Moreland, Larry W ^a,b  

^a University of Alabama at Birmingham   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MACROGOL; MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ACTIVITY; DRUG ACTIVITY; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 0032810459     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.4-5.552206     Document Type: Conference Paper

References (67)

1. Arend, W.P., Dayer, J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995, 38: 151-60.
2. Moreland, L.W., Heck, L.W. Jr., Koopman, W.J. Biologic agents for treating rheumatoid arthritis: Concepts and progress. Arthritis Rheum 1997, 40: 397-409.
3. Williams, R.O., Mason, L.J., Feldmann, M., Maini, R.N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994, 91: 2762-6.
4. Wooley, P.H., Whalen, J.D., Chapman, D.L. et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993, 36: 1305-14.
5. Williams, R.O., Ghrayeb, J., Feldmann, M, Maini, R.N. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995, 94: 433-9.
6. Wooley, P.H., Dutcher, J., Widmer, M.B., Gillis, S. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993, 11: 6602-7.
7. Van den Berg, W.B., Joosten, L.M. Helson, M., van de Loo, F.A. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994, 95: 237-42.
8. Keffer, J., Probert, L., Cazlaris, H. et al. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 1991, 10: 4025-31.
9. Eliaz, R., Wallach, D., Kost, J. Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p55 TNF receptor. Cytokine 1995, 9: 482-7.
10. Joosten, L.A.B., Helsen, M.M.A., van de Loo, F.A.J., van den Berg, W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNF-α, anti-IL-1α/β and IL-1RA. Arthritis Rheum 1996, 39: 797-809.
11. Van de Loo, F.A.J., Joosten, L.A.B., van Lent, P.L.E.M., Arntz, O.J., van den Berg, W.B. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: Effect of in situ blocking murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995, 38: 164-72.
12. Kuiper, S., Joosten, L.A.B., Bendele, A.M. et al. Different roles of tumor necrosis factor-α and interleukin-1 in murine streptococcal cell wall arthritis. Cytokine, in press.
13. Arend, W.P. Interleukin-1 receptor antagonist: A new member of the interleukin family. J Clin Invest 1991, 88: 1445-51.
14. Campion, G.V., Lebsack, M.E., Lookabaugh, J. et al. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39: 1092-101.
15. Bresnihan, B., on behalf of the collaborating investigators, Lookabaugh, J., Witt, K., Musikic, P. Treatment with recombinant human interleukin-1 receptor antagonist (rhuIL-1ra) in rheumatoid arthritis (RA): Results of a randomized double-blind, placebo-controlled multicenter trial. Arthritis Rheum 1996, 39: S73.
16. Felson, D.T., Anderson, J.J., Boers, M. et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 18: 727-35.
17. Symons, J.A., Eastgate, J.A., Duff, G.W. Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med 1991, 174: 1251-4.
18. Arend, W.P., Malyak, M., Smith, M.F. Jr. et al. Binding of the IL-1α, IL-1β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors by synovial fluids. J Immunol 1994, 153: 4766.
19. Drevlow, B., Capezio, J., Lovis, R., Jacobs, C., Landay, A., Pope, R.M. Phase I study of recombinant human interleukin-1 receptor (rhu IL-1R) administered intra-articularly in active rheumatoid arthritis. Arthritis Rheum 1993, 26 (Suppl. 9): S39.
20. Drevlow, B.E., Lovis, R., Haag, M.A. et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996, 39: 257-65.
21. Elliott, M.J., Maini, R.N., Feldmann, M. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993, 36: 1681-90.
22. Elliott, M.J., Maini, R.N., Feldman, M. et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344: 1105-10.
23. Elliott, M.J., Maini, R.N., Feldmann, M. et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344: 1125-7.
24. Maini, R.N., Breedveld, F.C., Kalden, J.R. et al. Low-dose methotrexate (MTX) suppresses anti-globulin responses and potentiates efficacy of a chimeric monoclonal anti-TNF-α antibody (cA2) given repeatedly in rheumatoid arthritis (RA). Arthritis Rheum 1997, 40 (Suppl.): S126.
25. Kavanaugh, A.F., Cush, J.J., St. Clair, E.W. et al. Anti-TNF-α monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): Results of a double-blind, placebo-controlled trial. Arthritis Rheum 1996, 39(Suppl.): S123.
26. Tak, P.P., Taylor, P.C., Breedveld, F.C. et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39: 1077-81.
27. Lorenz, H.-M., Antoni, C., Valerius, T. et al. In vivo blockade of TNF-a by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: Short-term cellular and molecular effects. J Immunol 1996, 156: 1646-53.
28. Paleolog, E.M., Hunt, M., Elliott, M.J., Feldmann, M., Maini, R.N., Woody, J.N. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996, 39: 1082-91.
29. Rankin, E.C.C., Choy, E.H.S., Kassimos, D. et al. The therapeutic effects of an engineered human anti-tumour necrosis factor α antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1992, 34: 334-42.
30. Stack, W.A., Mann, S.D., Roy, A.J. et al. Randomized controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997, 349: 521-4.
31. Targan, S.R., Hanover, S.B., van Deventer, S.J.H. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. New Engl J Med 1997, 337: 1029-35.
32. Tartaglia, L.A., Weber, R.F., Figari, I.S., Reynolds, C., Palladino, M.A. Jr. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991, 88: 9292-6.
33. Lantz, M., Bjornberg, F., Olsson, l., Richter, J. Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms. J Immunol 1994, 152: 1362-9.
34. Pennica, D., Lam, V.T., Mize, N.K. Biochemical properties of the 75-kDa tumor necrosis factor receptor: characterization of ligand binding, internalization, and receptor phosphorylation. J Biol Chem 1992, 267: 21172-8.
35. Tartaglia, L.A., Weber, R.F., Figari, I.S. et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991, 88: 9292-6.
36. Olsson, I., Lantz, M., Nilsson, E. et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989, 42: 270-5.
37. Ferrante, A., Hauptmann, B., Seckinger, P. et al. Inhibition of tumor necrosis factor α (TNF-α)-induced neutrophil respiratory burst by a TNF inhibitor. Immunology 1991, 72: 440-2.
38. Tilg, H., Shapiro, L., Atkins, M.B. et al. Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. J Immunol 1993, 151: 3299-307.
39. Cope, A.P., Gibbons, D.L., Aderke, D. et al. Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4: Upregulation of p55 and p75 TNF-R on synovial joint mononuclear cells. Cytokine 1993, 5: 205-12.
40. Taylor, D.J. Cytokine combinations increase p75 tumor necrosis factor receptor binding and stimulate receptor shedding in rheumatoid synovial fibroblasts. Arthritis Rheum 1994, 37: 232-5.
41. Gatanaga, T., Hwang, C.D., Kohr, W. et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990, 87: 8781-4.
42. Mohler, K.M., Torrance, D.S., Smith, C.A. et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993, 151: 1548-61.
43. Moreland, L.W., Margolies, G.R., Heck, L.W. et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996, 23: 1849-55.
44. Moreland, L.W., Baumgartner, S.W., Schiff, M.H. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl J Med 1997, 3337: 141-7.
45. Weinblatt, J., Moreland, L.W., Schiff, M.H. et al. Long-term and phase III treatment of DMARD-failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc; Enbrel ™). Arthritis Rheum 1997, 40(Suppl.): S126.
46. Eason, J.D., Pascual, M., Wee, S. et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 1996, 61: 224-8.
47. Mohler, K.M., Torrance, D.S., Smith, C.A. et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993, 151: 1548-61.
48. Beutler, B., van Huffel, C. Unraveling function in the TNF ligand and receptor families. Science 1994, 264: 667-8.
49. Furst, D., Weisman, M., Paulus, H. et al. Neutralization of TNF by Lenercept (TNFr55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: Results of an us phase II trial. Arthritis Rheum 1996, 39(Suppl.): S243.
50. Ralph, P., Nakoinz, I., Sampson-Johannes, A. et al. IL-10, T-lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992, 148: 808-14.
51. Cassatella, M.A., Meda, L., Bonora, S., Ceska, M., Constantin, G. Interleukin (IL)-10 inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes: Evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993, 178: 2007-211.
52. Fiorentino, D.F., Zlotnik, A., Mossman, T.R., Howard, M., O'Garra, A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147: 3815-22.
53. Vannier, E., Miller, L.C., Dinarello, C.A. Coordinated antiinflammatory effects of interleukin-4: Interleukin-4 suppresses interleukin-1 production but upregulates gene expression and synthesis of interleukin-1 receptor antagonist. Proc Natl Acad Sci USA 1992, 89: 4076-80.
54. Allen, J.B., Wong, H.L., Costa, G.L. Bienkowski, M.J., Wahl, S.M. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 1993, 151: 4344-51.
55. Trepicchio, W.L., Bozza, M., Pedneault, G., Dorner, A.J. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996, 157: 3627-34.
56. Trepicchio, W.L., Wang, L.L., Bozza, M., Dorner, A.J. Interleukin-11 regulates macrophage effector function through inhibition of NF-κB. J Immunol 1997, 159: 5661-70.
57. Lentsch, A.B., Shanley, T.P., Sarma, V., Ward, P.A. In vivo suppression of NF-κB and preservation of IK-Bα by interleukin-10 and interleukin-13. J Clin Invest 1997, 100: 2443-8.
58. Joosten, L.A.B., Lubberts, E., Durez, P. et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997, 40: 249-60.
59. Wendung, D., Racadot, E., Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J Rheumatol 1993, 20: 259-62.
60. Xing, Z., Gauldie, J., Cox, G. et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998, 101: 311-20.
61. Jacob, C.O., Holoshitz, J., van der Meide, P., Strober, S., McDevitt, H.O. Heterogeneous effects of IFN-γ in adjuvant arthritis. J Immunol 1989, 142: 1500-5.
62. Mauritz, N.J., Holmdahl, R., Jonsson, R., van der Meide, P.H., Scheynius, A., Klareskog, L. Treatment with interferon-γ triggers the onset of collagen arthritis in mice. Arthritis Rheum 1988, 31: 1297-304.
63. Cannon, G.W., Pincus, S.H., Emkey, R.D. Double-blind trial of recombinant interferon-γ versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1989, 32: 964-73.
64. Lemmel, E.M., Gaus, W., Hofschneider, P.H. Multicenter double-blind trial of interferon-γ versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1991, 34: 1621-2.
65. Veys, E.M., Mielants, H., Verbruggen, G. et al. Interferon-γ in RA: A double-blind study comparing human recombinant interferon-γ with placebo. J Rheumatol 1988, 15: 570-4.
66. Machold, K.P., Neumann, K., Smolen, J.S. Recombinant human interferon-γ in the treatment of rheumatoid arthritis: Double-blind placebo-controlled study. Ann Rheum Dis 1992, 51: 1039-43.
67. Veys, E.M., Menkes, C.J., Emery, P. A randomized, double-blind study comparing twenty four week treatment with recombinant interferon-γ versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1997, 40: 62-8.